Mizuho Securities analyst Salim Syed has maintained their bullish stance on UBX stock, giving a Buy rating yesterday.
Salim Syed’s rating is based on the analysis of the recent data from Unity Biotechnology’s UBX1325 Ph2b ASPIRE study. Although the study did not meet its primary endpoint of non-inferiority compared to aflibercept at the 20-week mark, the overall data from the 36-week study showed that UBX1325 was non-inferior to aflibercept in 9 out of 10 measurement points. This suggests that the drug has potential, especially considering that the miss was narrowly driven by the 20-week data.
Furthermore, a pre-specified analysis of a subgroup with baseline CST<400µm, which constituted about 60% of the study population, showed non-inferiority at all time points through 36 weeks. The safety profile of UBX1325 was also consistent with previous studies, indicating a favorable risk-benefit ratio. These factors contribute to a positive outlook for Unity Biotechnology, justifying the Buy rating despite the initial setback in the primary endpoint.
Syed covers the Healthcare sector, focusing on stocks such as Vaxcyte, Cytokinetics, and BridgeBio Pharma. According to TipRanks, Syed has an average return of -6.8% and a 38.10% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $4.00 price target.